Kaigene Inc. has entered into an exclusive global licensing agreement with Celltrion Inc. for two of Kaigene's nonclinical-stage assets, KG006 and KG002.

Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune ...

November is National Diabetes Awareness Month, a time to talk about the disease that affects more than 38 million people ...

U.S. President Donald Trump's embrace of an old generic drug called leucovorin for use against a rare disorder that causes ...

Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

SAN FRANCISCO -- Two studies demonstrated the benefits of treating juvenile myasthenia gravis (MG) with newer drugs.

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation to Augurex Life Sciences’ SPINEstat ...

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition ...